Goal: This study aims to improve our understanding of the genetic markers associated with severe acne and the adverse response to oral isotretinoin (Accutane) treatment, leading to the development of safer and more effective treatments.
Principal Investigator: Dr. Russell Hall (interim)
Study Details: This study enrolled 122 participants who were diagnosed with severe acne vulgarism and had received oral isotretinoin treatment (eg. Accutane, Amnesteem, Claravis, Sotret). The geographic criteria were waived for this study. Participants donated blood and urine samples and completed a medical questionnaire about general health and a second questionnaire pertaining to their acne diagnosis and treatment.